Shilanski & Associates’s Ascendis Pharma A/S ASND Stock Holding History

Shilanski & Associates’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$259K	Buy	+1,304	New	+$243K	0.07%	87

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Shilanski & Associates's ASND Position: Q3 2025 in Review

Shilanski & Associates opened a new position in Ascendis Pharma A/S (ASND) in Q3 2025: 1,304 shares worth $259K. The stake represents 0.07% of the portfolio and ranks #87 among its holdings.

279 funds tracked by Wall St. Rank hold ASND as of Q3 2025.

Shilanski & Associates held 1,304 shares of Ascendis Pharma A/S worth $259K as of Q3 2025.
Ascendis Pharma A/S was a new Shilanski & Associates position in Q3 2025.
Ascendis Pharma A/S made up 0.07% of Shilanski & Associates's portfolio in Q3 2025, its #87 holding.
279 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.